Laurus Injects Tech In Pharma
Under Satyanarayana Chava, the company has entered cutting-edge areas such as gene therapy and rare diseases.
Under Satyanarayana Chava, the company has entered cutting-edge areas such as gene therapy and rare diseases.
This smallcap stock has more than doubled investors’ money in 12 months, rising from its 52-week low of ₹197.50 to an all-time high of ₹461.95 in intraday trade on the BSE.